- Home
- CCS vs CPRX Comparison
CCS vs CPRX Comparison
Compare CCS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCS
- CPRX
- Stock Information
- Founded
- CCS 2000
- CPRX 2002
- Country
- CCS United States
- CPRX United States
- Employees
- CCS N/A
- CPRX N/A
- Industry
- CCS Homebuilding
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CCS Consumer Discretionary
- CPRX Health Care
- Exchange
- CCS Nasdaq
- CPRX Nasdaq
- Market Cap
- CCS 2.7B
- CPRX 2.6B
- IPO Year
- CCS 2014
- CPRX 2006
- Fundamental
- Price
- CCS $71.72
- CPRX $21.96
- Analyst Decision
- CCS Buy
- CPRX Strong Buy
- Analyst Count
- CCS 4
- CPRX 8
- Target Price
- CCS $104.00
- CPRX $32.50
- AVG Volume (30 Days)
- CCS 409.8K
- CPRX 1.1M
- Earning Date
- CCS 04-23-2025
- CPRX 02-26-2025
- Dividend Yield
- CCS 1.62%
- CPRX N/A
- EPS Growth
- CCS 29.19
- CPRX 107.94
- EPS
- CCS 10.40
- CPRX 1.31
- Revenue
- CCS $4,398,288,000.00
- CPRX $491,734,000.00
- Revenue This Year
- CCS $12.41
- CPRX $15.61
- Revenue Next Year
- CCS $8.21
- CPRX $13.44
- P/E Ratio
- CCS $6.90
- CPRX $16.76
- Revenue Growth
- CCS 19.12
- CPRX 23.49
- 52 Week Low
- CCS $66.72
- CPRX $14.47
- 52 Week High
- CCS $108.42
- CPRX $24.64
- Technical
- Relative Strength Index (RSI)
- CCS 47.78
- CPRX 48.22
- Support Level
- CCS $66.72
- CPRX $20.46
- Resistance Level
- CCS $72.80
- CPRX $23.39
- Average True Range (ATR)
- CCS 2.40
- CPRX 0.85
- MACD
- CCS 0.13
- CPRX -0.02
- Stochastic Oscillator
- CCS 60.34
- CPRX 47.92
About CCS Century Communities Inc.
Century Communities Inc is a construction company that focuses on the residential market. It has five homebuilding segments: West, Mountain, Texas, Southeast, and Century Complete. Its sixth reportable segment is financial services operations, which provides mortgage, title, and insurance services to homebuyers. It has acquired land for homebuilding operations with the primary intent to develop and construct single-family detached or attached homes for sale on the acquired land. The company sells homes through its own sales representatives and independent real estate brokers. It also advertises directly to potential homebuyers through the Internet, newspapers, and trade publications. The company generates the majority revenue from the Mountain segment.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.